Risk factors
Jazz Pharmaceuticals (JAZZ) risk factors
Item 1A of every Jazz Pharmaceuticals plc 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors52 risks12 new6 dropped21 reworded
Jazz Pharmaceuticals faces increased scrutiny over drug pricing, government reimbursement programs, and compliance with controlled substance regulations.
Filed Feb 24, 2026 - FY2024 10-K risk factors46 risks
Revenue concentration on the oxybate franchise and Epidiolex dominates risk exposure.
Filed Feb 26, 2025